Curcumin analogues as possible anti-proliferative & anti-inflammatory agents

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Drug Discovery

Background:

• Curcumin, a natural compound, possesses anti-inflammatory and anti-proliferative properties but faces limitations.
• Multi-target agents are desirable for complex diseases.
• Developing novel analogues can enhance efficacy and overcome limitations.

Purpose of the Study:

• To design, synthesize, and evaluate novel curcumin analogues as multi-target agents.
• To assess the anti-inflammatory and anti-proliferative activities of these analogues.
• To investigate their inhibitory potential against soybean lipoxygenase (LOX) and aldose reductase (ALR2).

Main Methods:

• In vitro and in vivo testing of synthesized curcumin analogues.
• Evaluation of anti-proliferative activity against human cancer cell lines.
• Lipophilicity determination using RPTLC and theoretical calculations.
• Molecular docking simulations on LOX and ALR2 enzymes.

Main Results:

• Compounds 1b and 2b showed stronger inhibition of soybean lipoxygenase (LOX) than curcumin.
• Analogue 1b was identified as the most potent aldose reductase (ALR2) inhibitor.
• Compounds 1a and 1f demonstrated in vivo anti-inflammatory activity comparable to indomethacin, with 1i showing even higher activity.
• Compounds 1a, 1b, 1d, and 2b exhibited significant growth inhibition against three human cancer cell lines, surpassing curcumin's activity.
• Docking simulations revealed favorable binding of compound 1b in the ALR2 active site.

Conclusions:

• Novel curcumin analogues possess significant anti-inflammatory and anti-proliferative potential.
• These analogues demonstrate multi-target activity, inhibiting key enzymes like LOX and ALR2.
• Structural modifications of curcumin can lead to enhanced therapeutic properties for various diseases.